Insmed Incorporated
INSM
Pozycja w akcjach
#1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Cena akcji
$95.65
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$20.89B
Zmiana (1 dzień)
-0.65%
Zmiana (1 rok)
-43.04%
Kraj
US
Handel Insmed Incorporated (INSM)
Kategoria
Healthcare
Wskaźnik P/S dla Insmed Incorporated (INSM)
Wskaźnik P/S na dzień October 2026 TTM: 18.77
Według najnowszych raportów finansowych i ceny akcji Insmed Incorporated, obecny wskaźnik P/S (TTM) wynosi 18.77. Na koniec 2023 wynosił 14.26.
Historia wskaźnika P/S dla Insmed Incorporated od 2000 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 18.77 | -39.72% |
| 2024 | 31.14 | 118.38% |
| 2023 | 14.26 | 42.32% |
| 2022 | 10.02 | -38.17% |
| 2021 | 16.20 | -18.01% |
| 2020 | 19.76 | 33.56% |
| 2019 | 14.80 | -85.57% |
| 2018 | 102.51 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 57.87 | 11.92% |
| 2013 | 51.71 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | 16.12 | 33.50% |
| 2010 | 12.08 | 27.98% |
| 2009 | 9.44 | 93.34% |
| 2008 | 4.88 | -61.16% |
| 2007 | 12.57 | -85.15% |
| 2006 | 84.64 | -88.45% |
| 2005 | 732.99 | 16.61% |
| 2004 | 628.56 | -10.83% |
| 2003 | 704.88 | 9,371.65% |
| 2002 | 7.44 | -98.25% |
| 2001 | 424.21 | -59.94% |
| 2000 | 1.06K | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | -46.61% |
US
|
|
| 40.55 | 116.02% |
US
|
|
| 3.96 | -78.90% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -45.95% |
NL
|
